Tim McCarthy Appointed as Non-executive Chairman
30th September 2015 - 10:50 am
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.
Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.
A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management.
Commenting on Tim McCarthy’s appointment, Dimitri Dimitrou, Chief Executive Officer, said:
“We are delighted to have Tim join ImmuPharma as Chairman. This appointment represents a further strong addition to the Board. Tim’s commercial and industry background together with capital markets experience will be extremely valuable as ImmuPharma progresses its lead compound, Lupuzor™, through its pivotal Phase III trial, as well as providing guidance on ImmuPharma’s long term business strategy.”
Ark Analytics Solutions Limited
BBN International Limited
Expedeon Holdings Limited
Frangipani Dreams Limited
Harvard Healthcare Limited
Spear Therapeutics Limited
Wise Old Owl Limited
Directorships in the Last 5 years
Retail Service Team Limited*
*This company entered into a Creditors Voluntary Winding-up on 12th December 2013, 8 months after Mr McCarthy’s resignation of directorship. It was dissolved on 4 June 2015. There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.